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Summary (40 words): In a large census-based community serosurvey in Blantyre, Malawi adult 
HBsAg prevalence was 5.1%, and 0.3% among vaccine-eligible children. Estimated vaccine impact 
was 95.8% (95% CI 70.3-99.4). Up to 9% of HBsAg-positive adults had an unmet need for antiviral 
treatment. 
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Hepatitis B is the leading cause of cirrhosis and liver cancer in sub-Saharan Africa. To reduce 
hepatitis-associated mortality, antiviral treatment programmes are needed. We estimated 
prevalence, vaccine impact and need for antiviral treatment in Blantyre, Malawi to inform an 
effective public health response.   
Methods 
We conducted a household study in Blantyre in 2016-2018. We selected individuals from a census 
using random sampling and estimated age-sex-standardised HBsAg seroprevalence. Impact of infant 
hepatitis B vaccination, which began in 2002, was estimated by binomial log-linear regression 
comparing individuals born before and after vaccine implementation. In HBsAg-positive adults, 
eligibility for antiviral therapy was assessed. 
Results 
Of 97,386 censused individuals, 6,073 (median age 18 years; 56.7% female) were sampled. HBsAg 
seroprevalence was 5.1% (95% CI 4.3–6.1) among adults and 0.3% (0.1–0.6) among children born 
after vaccine introduction. Estimated vaccine impact was 95.8% (70.3–99.4). Of HBsAg-positive 
adults, 26% were HIV-positive. Among HIV-negative individuals, 3%, 6% and 9% were eligible for 
hepatitis B treatment by WHO, European and American hepatology association criteria, respectively. 
Conclusions 
Infant HBV vaccination has been highly effective in reducing HBsAg prevalence in urban Malawi. Up 
to 9% of HBsAg-positive HIV-negative adults are eligible, but have an unmet need, for antiviral 
therapy.  
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In sub-Saharan Africa, chronic hepatitis B is the leading cause of liver cirrhosis and hepatocellular 
carcinoma (HCC).[1] HCC is the second-highest incident cancer in men and fourth among women in 
the region, and is usually diagnosed at an advanced stage when curative treatment is no longer 
possible.[2, 3] In 2016, the World Health Assembly set ambitious targets to reduce the incidence of 
viral hepatitis by 90% and mortality by 65% by 2030, calling for improved efforts to prevent, 
diagnose and treat chronic hepatitis B.[4] Modelling studies project that while hepatitis B prevalence 
will decline among children due to vaccination programmes, hepatitis B-related mortality will 
increase by 2030 in sub-Saharan Africa without implementation of treatment programmes for 
adults.[5] Data from Western and Asian cohorts show that i  chronic hepatitis B antiviral therapy 
results in several important outcomes including regression and reversal of liver fibrosis, reduction in 
HCC incidence, improved survival and increased quality of life.[6-8] In the Gambia, a community 
hepatitis B virus (HBV) screen-and-treat strategy was deemed to be feasible and cost-effective.[9] 
The infant hepatitis B vaccine, was introduced into national immunisation schedules across sub-
Saharan Africa between 1994 and 2014, and in Malawi in 2002. The World Health Organization 
(WHO) recommends commencing the first dose at birth but this has not been implemented in most 
sub-Saharan African countries, including Malawi.[10] In 2019, three-dose coverage starting at 6 
weeks was median 87% (interquartile range (IQR) 74-93) across the region and 95% in Malawi.[11] A 
community assessment of vaccine impact has not previously been conducted in southern Africa, 
outside of South Africa, and there are therefore no data for Malawi. 
In a previous systematic review, we estimated that hepatitis B surface (HBsAg) prevalence was 8% 
among adults in Malawi, but observed that available data were predominantly based on 
convenience sampling, hence at significant risk of bias.[12] Estimates of the community-level burden 
of hepatitis B virus (HBV) infection and disease, and the projected need for hepatitis B treatment are 
required to inform an effective public health response.[4] To address a significant gap in knowledge, 



















HBsAg seroprevalence and impact of hepatitis B vaccination and to estimate the population-level 
eligibility and unmet need for hepatitis B treatment. 
 
METHODS 
Census and serological survey 
Individuals of all ages resident in Ndirande, Blantyre, Malawi were randomly selected from a 
population demographic census and invited to participate in a serosurvey in 2016-2018. Ndirande is 
an unplanned urban township in the north of Blantyre. Malawi is a low-income country in southern 
Africa with a life expectancy at birth of 64 years and national HIV prevalence of 10.6% (95% CI 9.9-
11.2) among adults.[13] 
We used single-stage random probability sampling, with age-stratification to oversample younger 
children, as part of a co-incident typhoid epidemiology study (Strategic Typhoid Alliance across 
Africa and Asia).[14, 15] Global positioning satellite (GPS) co-ordinates of households were recorded 
(eTrex 30x, Garmin, USA) to assess spatial distribution of selected individuals. If a randomly selected 
individual in the serosurvey could not be located or did not consent, another household member 
from the same age-stratification group was requested to participate, or secondarily, a replacement 
was selected by further randomisation from the census age-stratum. Educational, marital and 
employment data were recorded from serosurvey participants. We estimated a sample size 
requirement of 5913 based on an anticipated HBsAg prevalence of 8.1% for precision of 1% 
(Appendix 1). Vaccination status of children aged ≤10 years was obtained from the family-held 
vaccine record or if unavailable, parent or guardians’ report. Venous EDTA samples were collected in 
consenting participants’ households, stored in cool boxes and transported to the study laboratory. 





















Evaluation of HBV disease  
We returned to households of individuals aged ≥16 years who tested HBsAg-positive by laboratory 
enzyme immunoassay and invited them to participate in an evaluation of treatment eligibility based 
on WHO 2015, European Association for the Study of the Liver 2017 (EASL) and American 
Association for the Study of the Liver (AASLD) 2018 criteria (Appendix 2).[8, 16, 17] For pregnant 
women, for whom transient elastography is not recommended, we returned >6 weeks after delivery 
to invite them to participate. Inclusion criteria for evaluation of treatment eligibility were HBsAg 
seropositivity, residence in the study catchment area and capacity to consent. We conducted 
assessments in  community halls close to participants’ residences. Rapid point-of-care HIV testing 
was offered in accordance with national guidelines using Determine anti-HIV (Alere, South Africa) for 
screening, followed by confirmation with Uni-Gold HIV (Trinity Biotech, Ireland). We performed 
clinical examination to elicit signs of chronic liver disease. We assessed liver stiffness using transient 
elastography in the right mid-axillary intercostal space after fasting for >3 hours (FibroScan 430 Mini, 
Echosens, France). Reliability criteria were IQR/median <0.3 if >7.1kPa.[18] We applied categorical 
interpretative cut-offs of 7.9 kPa for significant fibrosis (F2) and 9.5 kPa for cirrhosis (F4) according to 
cross-sectional comparative data from the Gambia and Senegal.[19] Participants meeting EASL 
criteria were referred for treatment with tenofovir. 
 
Laboratory investigations 
Laboratory investigations were performed in the Malawi-Liverpool-Wellcome Trust Laboratories in 
Blantyre. We tested for HBsAg using the Monolisa HBsAg-Ultra (Bio-Rad, France) enzyme-linked 
immunoassay (ELISA in accordance with manufacturer instructions. Samples showing intermediate 
reactivity (sample/cut-off ratio >0.9) and all positive samples were repeated in duplicate. Hepatitis B 
e antigen (HBeAg), anti-HBe, hepatitis C antigen/antibody (HCV Ag/Ab) and anti-hepatitis delta virus 
(anti-HDV) were tested by ELISA using Monolisa HBeAg-Ab (Bio-Rad), Monolisa HCV Ag-Ab ULTRA v2, 
(Bio-Rad) and ETI-AB-DELTAK-2 (Diasorin, Italy), respectively. HBV DNA was quantified using an in-
house real-time PCR, with a lower limit of quantification of 34 IU/ml (Appendix 3). ALT was 
measured using an automated assay with an upper limit of normal of 32 U/L (AU480, Beckmann 





















Ethical permission to conduct the study was obtained from the National Health Sciences Research 
Committee of Malawi (16/11/1698 and 15/5/1599) and the University of Liverpool (reference 1954). 
Participants in the serological survey and clinical evaluation provided written informed consent. The 
study was conducted in accordance with the Declaration of Helsinki (2013). 
 
Statistical analysis 
We estimated population HBsAg prevalence using survey design weights from age-stratification and 
used post-stratification iterative proportional fitting with 5-year age-sex groups from the census to 
adjust estimates to the population distribution. In a sensitivity analysis, we also adjusted for 
geographic area to account for geographic variation in response rate. Where date of birth was 
unknown, we estimated the year mid-point from reported age. We assessed spatial clustering of 
HBsAg-positive participants using Getis-Ord Gi* and Anselin Local Moran’s I statistics. Association 
between HBsAg and explanatory variables were assessed by binomial logistic regression, applying 
sampling probability weights. For multivariable model selection among participants ≥16 years we 
considered variables with p<0.25 in univariable analysis for inclusion and included a restricted cubic 
spline for age to account for variation in HBsAg prevalence with respect to age. To calculate 
socioeconomic status (SES), we analysed responses to a household economic survey from 12,080 
households (Appendix 4) using principal component analysis to derive relative wealth quintiles for 44 
areas represented in the serosurvey.[20] To estimate vaccine impact, we compared individuals born 
within 5 years prior to vaccine introduction in 2002 (aged between 15 and 21 years at the date of 
sampling) with those born within 5 years after vaccine introduction (aged 10 to 16 years), and in a 
sensitivity analysis, compared those born within 10 years before and after implementation. Ages in 
the two groups overlapped due to the 18-month duration of the serosurvey. Vaccine impact was 
calculated as (1-risk ratio (RR)) x 100) where RR was estimated from binomial log-linear regression, 
adjusted for survey weights. In sensitivity analyses, we compared the primary model with Poisson 
regression with robust standard errors and logistic regression models, and assessed the effect of 
adding participant age at sampling and 2-year birth cohort intervals as co-variates using the Wald 
test, to assess for an age-cohort effect. Analyses were conducted in ArcGIS Pro 2.4.1 (Esri, USA) and 






















HBsAg seroprevalence and vaccine impact 
Overall 6,073 individuals participated in the serological survey and were tested for HBsAg, from a 
total census population of 97,386 (Figure 1). Median age of serosurvey participants was 18 years 
(IQR 8-37) and 3,455/6,073 (56.7%) were female. This compares to a median age of 17 years (IQR 4-
32) and a female proportion of 51.5% in the national 2018 census.[21] The serosurvey oversampled 
younger children and older adults relative to the census distribution (Figure 2). A total of 160/6,073 
(2.6%) participants tested positive for HBsAg. No spatial clustering of HBsAg-positive individuals was 
observed with Getis-Ord Gi* and Anselin Local Moran’s I statistics (Appendix 5). The age- and sex-
standardised prevalence of HBsAg in the general population was 3.1% (95% confidence interval (CI) 
2.6–3.7). Prevalence peaked among males aged 30-39 years and declined among older adults (Figure 
3, Appendix 6). 
Vaccination status was obtainable from 1,172/2,085 (56.2%) children aged ≤10 years and 631/931 
(67.8%) children aged ≤5 years. Data sources comprised health records for 722/1,172 (61.6%) and 
parent/guardian report for 450/1,172 (38.4%). Completion of 3-dose HBV vaccination was reported 
for 1,141/1,172 (97.4%) children ≤10 years and 619/631 (98.1%) among children ≤5 years, for whom 
vaccine status was known. Vaccine coverage was associated with data source, with 96.5% reporting 
complete vaccination from health recor s and 98.6% from oral parental/guardian report, p=0.03. 
Only 31 children were ascertained to be unvaccinated and none tested HBsAg-positive. Standardised 
HBsAg prevalence was 0.6% (95% CI 0.2–1.4) among 913 children with unknown vaccination status, 
which was not significantly different from children completing all 3 doses (0.2%; 95% CI 0.1–0.8, 
p=0.26).  
 
Among children born after infant vaccine implementation in 2002, standardised HBsAg prevalence 
was 0.3% (95% CI 0.2–0.6), while among all adolescents and adults born prior to vaccine introduction 
it was 5.1% (95% CI 4.3–6.1) (Table 1). Vaccine impact was 95.9% (95% CI 70.6–99.4) in the primary 
analysis, comparing individuals born in the 5 years prior to vaccine introduction (aged 15-21 years) 
with those born in the 5 years afterwards (aged 10-16 years). In a sensitivity analysis, comparing 
those born 10 years before and after vaccine introduction, vaccine impact was 93.3% (95% CI 83.1–
97.4). Sensitivity analyses including Poisson regression with robust standard errors and logistic 



















variables did not indicate a significant age-cohort effect. Post-stratification adjustment for 
geographic area did not affect prevalence estimates (Appendix 8). By univariate analysis, HBsAg-
positive individuals aged ≥16 years were more likely to be male, in paid or self-employment, and to 
be married, separated or divorced. No association with educational attainment or regional SES 
status was observed. In a multivariable model, greater odds of HBV infection were observed in males 
and separated or divorced individuals (Table 2). 
 
Treatment eligibility 
Evaluation for treatment eligibility occurred a median of 4.9 months (IQR 2.2, 7.6) after the 
serosurvey. Of 150 HBsAg-positive serosurvey participants aged ≥16 years, we were able to locate 
114 in the township (76.0%); four had died, two were unable to provide consent and nine had 
moved outside the region (Figure 4). A total of 94/114 (82.5%) eligible individuals agreed to 
participate in evaluation of treatment eligibility. Participants had a higher level of education, higher 
SES, and higher rate of employment relative to non-participants (Appendix 9).  
Characteristics of the clinical evaluation population are shown in Table 3. Of 93/94 (98.9%) who 
agreed to HIV testing, 24/93 (25.8%) were HIV positive, of which 7 (29.1%) were newly diagnosed. 
Median CD4 count was 519 cells/mm3 (IQR 412, 577). Of those with HIV/HBV co-infection, 16/24 
(67%) were on antiretroviral therapy (ART), all of which contained HBV-active agents including 
tenofovir, and all 16 had HBV DNA suppression <34 IU/ml. Anti-HDV was positive in 2/94 (2%) and 
HCV Ag/Ab was negative in all participants. HBeAg was positive in 10/94 (11%): 25% (6/24) among 
HIV-positive participants and 6% (4/69) among HIV-negative participants, p=0.02. In the HIV-
negative population, HBV DNA was >2000 IU/ml in 28% (19/69) and >20,000 IU/ml in 16% (11/69), 
and 3% (2/69) had an ALT >ULN. Liver stiffness exceeding 9.5kPa was observed in 3/69 (4%) of the 
HIV negative and 1/24 (4%) of the HIV positive population. Following clinical evaluation of the 
HBsAg-positive and HIV-negative population using WHO, EASL and AASLD criteria, 2.9%, 5.7% and 
8.7% met eligibility criteria for HBV treatment, respectively (Figure 4). Projecting EASL criteria to the 
national population of 17.6 million, this represents an estimated 25,586 individuals (95% CI 7,172 –






















Fifteen years after implementation of the hepatitis B vaccination programme in Malawi, we 
observed a vaccine impact of 96%, by comparison of people born 5 years before and after vaccine 
introduction. Coverage exceeding 97% was observed among children for whom vaccination status 
could be ascertained. These encouraging data show that in the setting of very high vaccine coverage, 
HBV vaccination has been highly effective, with a low residual HBsAg prevalence (<0.5%)among 
children born after HBV vaccination was added to the enhanced programme of immunization. 
There are limited existing data evaluating community HBV vaccine performance from sub-Saharan 
Africa. In the Gambia, among 753/2670 young adults who could be linked to vaccination data, 
estimated vaccine efficacy was 94% (95% CI 77-99).[22] In Senegal estimated vaccine efficacy was 
95% (95% CI 77- 99) among 9-12 year old participants of a HBV vaccination study.[23] In a household 
survey in South Africa, HBsAg prevalence was 0.9% among 15-19 year olds born after vaccine 
implementation, relative to 2.8% among those born before implementation.[24] In a sample of 18-
month old children attending vaccine clinics in South Africa, HBsAg prevalence was 0.4%, relative to 
historical pre-vaccination prevalence of 9.9% in the Eastern Cape.[25] In serosurveys in Ethiopia and 
Nigeria, in the setting of lower vaccine coverage rates ranging from 55-85%, direct vaccine 
effectiveness estimates ranged from 66-81%.[26, 27] Collectively these studies show vaccination in 
sub-Saharan Africa has had a significant impact in reducing HBV prevalence among children but also 
highlight the paucity of adequately-powered representative community assessments across much of 
the region, and the importance of achieving high vaccine coverage. Maternally-acquired HBV is 
associated with an increased risk of chronicity and development of cirrhosis,[28] and is not 
prevented by vaccination beginning at 6 weeks. Evaluation of transmission rates from HBsAg-
positive mothers are required to better assess the need for birth-dose vaccination and antenatal 
maternal antiviral therapy.[29]  
To date there are very limited representative data on the unmet need for antiviral therapy at the 
community level . Based on Malawi’s 2018 census population of 17.6 million people, we estimate 
that 25,586 HIV-negative people (95% CI: 7,225–65,657) are eligible, and have an unmet need, for 
HBV treatment by EASL criteria. This compares to an estimated 970,000 adults living with HIV of 
whom 810,000 are currently receiving ART [13], highlighting that HBV antiviral treatment is an 
achievable public health goal. A quarter of HBsAg-positive adults at the community level had HIV co-



















suppression. This is consistent with results of a national HIV survey in which 68% of individuals had 
HIV virological suppression, demonstrating the remarkable progress Malawi is making toward HIV 
control.[13] HIV treatment programmes represent a model for HBV due to similarities, including the 
need for lifelong antiviral therapy including tenofovir, and the potential to share clinic staff, facilities 
and laboratory equipment.[1]  
In our population serosurvey, we observed low HBsAg prevalence in vaccine eligible children, a peak 
in the 30-40 year age group and declining prevalence among older adults. Declining prevalence after 
40 years may be due to spontaneous HBsAg clearance, or death from cirrhosis or HCC or from 
infections that share epidemiological risk factors.[30] Increasing prevalence between adolescence 
and 40 years may be the result of incident HBV transmission, or due to HIV prevention messaging 
such as promotion of condom use among younger cohorts.[13] A detailed understanding of 
transmission is limited by the cross-sectional design and lack of previous historical data in children 
for Malawi. A longitudinal cohort or a repeated cross-sectional survey is required to better elucidate 
trends in transmission. The lack of association we observed between HBV and socioeconomic status 
is in contrast to most infectious diseases, where poverty has a causal role. The population under 
study has high poverty levels and limited intra-sample variation in SES could cause a lack of 
observable association in this sample. Male gender was n independent risk factor for HBV infection 
among adults, in keeping with other studies from sub-Saharan Africa.[31] Causal mechanisms may 
include unsafe circumcision, shared razor blades and use of shared equipment at barbershops.[32] 
Modelling studies project that HBV antiviral treatment programmes are necessary to reduce HBV- 
associated mortality or mortality will rise beyond 2030, even in the context of effective infant 
vaccination.[5] Thus the success of the vaccination programme we observed does not abrogate 
responsibility to tackle the anticipated rise in adult liver disease. In this community, by use of WHO, 
EASL or AASLD criteria, 3, 6 and 9% HBsAg-positive individuals respectively were eligible for 
treatment.[8, 16, 17] Two previous community studies have assessed HBV treatment eligibility in 
sub-Saharan Africa, in the Gambia and Zambia. In the Gambia, 4.4% of community participants and 
9.7% of HBsAg-positive blood donors were eligible for treatment, based on EASL 2012 criteria.[33] In 
Zambia 10% were treatment eligible by WHO criteria and 17% by EASL 2017 criteria.[34] In a 
hospital-based sample in Ethiopia, 20% had cirrhosis and 25.2% required treatment by EASL 2012 
criteria.[35] These compare to estimates from a recent systematic review where globally, 12% of 
participants in community studies required treatment.[36] International treatment criteria are 
derived from European and Asian data, and prospective cohort data from sub-Saharan are required 



















the highest prevalence of hepatitis B globally.[37] Recent evidence from Ethiopia observed that 
WHO guidelines failed to identify as eligible for treatment 36% of patients with compensated 
cirrhosis, who are likely to benefit most from antiviral treatment.[38]  
Our study benefitted from significant strengths including a large sample size, an unbiased census-
based random population selection method, and the capacity for adjustment for undersampling of 
harder-to-reach demographic groups using the population census. We also used rigorous methods 
to assess treatment eligibility in line with international guidelines.  There are several limitations to 
this analysis. First due to high vaccine coverage we were unable to estimate vaccine effectiveness, 
with only 31 unvaccinated children identified in the sample. Instead, we estimated vaccine impact, 
comparing birth cohorts relative to the timing of national vaccine introduction. This approach relies 
upon an assumption that exposure risk is equivalent between the two groups. Pre-vaccination data 
among children were not available to facilitate a comparison of age-matched groups[12], although 
some age overlap between pre- and post-vaccination groups did occur due to the 18-month duration 
of the serosurvey. We also suffered from a low rate of confirmed vaccine coverage due to limited 
availability of parent-held vaccination records. Second, our findings may not be nationally or 
regionally generalisable since we sampled from an urban population where vaccine uptake exceeds 
national coverage.[11] In the 2018 population census, 84% of Malawians resided in rural areas. 
Third, reasons for refusal were not recorded during the serosurvey to assess nonresponse bias. We 
mitigated this potential bias using post-stratification weighting to adjust estimates to the population 
age and sex distribution and did not detect an influence of geographic non-response on estimates. 
Fourth, we were unable to locate a third of HBsAg-positive individuals, limiting the statistical power 
available to estimate eligibility. Non-participants had lower socioeconomic status and educational 
attainment which could have resulted in selection bias, and under-estimation of liver disease 
burden. Our cross-sectional assessment may have resulted in further under-estimation of the total 
need for treatment given that parameters used to assess eligibility such as HBV DNA and ALT may 
fluctuate and evolve over time. 
In conclusion, in urban Malawi, fifteen years of infant HBV vaccination has been associated with a 
vaccine impact of 96%. Among HIV-negative individuals, antiviral therapy was required in 3-9% of 
HBsAg-positive adults, a significant unmet need. This is an achievable public health goal and an 
opportunity to prevent cirrhosis and reverse trends in rising hepatitis B associated mortality. 
Research to evaluate longitudinal performance of treatment eligibility criteria and to support 
treatment programme implementation are required to eliminate HBV as a public health threat in 
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Table 1: Prevalence of hepatitis B surface antigen stratified by birth date and vaccination status 






Risk ratio  
(95% CI) 
P value 
 Frequency  % (95% CI) % (95% CI)   
All individuals 160/6073 2.6 (2.3 – 3.1) 3.2 (2.7 – 3.7)   
Birth date relative to 
vaccine introductionb  
     
 5 yr before vaccine 15/500 3.0 (1.8 – 4.9) 2.9 (1.8 – 4.7) Reference  
 5 yr after vaccine 1/758 0.1 (0.02 – 0.7) 0.1 (0.02 – 0.8) 0.04 (0.06 – 
0.29) 
0.001 
 10 yr before vaccine 30/884 3.4 (2.4 – 4.8) 3.6 (2.5 – 5.1) Reference  
 10 yr after vaccine 5/1932 0.3 (0.1 – 0.6) 0.2 (0.1 – 0.6) 0.07 (0.03 – 
0.17) 
<0.0001 
 All before vaccine  152/3280 4.6 (4.0 – 5.4) 5.1 (4.3 – 6.0) Reference  
 All after vaccine  9/2793 0.3 (0.2 – 0.6)  0.3 (0.2 – 0.6) 0.06 (0.03- 0.12) <0.0001 
Vaccination status 
for age ≤10 years 






0.3 (0.1 – 0.8) 
 
 





 Unknown status c 5/913 0.5 (0.2 – 1.3) 0.6 (0.2 – 1.4) 2.3 (0.5 – 10.2) 0.26 
 Incomplete d 0/31 0.0 (0.0 – 11.0) - -  
 
a 
Standardised to census age and sex distribution. 
b
Hepatitis B vaccination was introduced on 1
st
 January 2002. 
c
Participants born after vaccine introduction for whom vaccination status could not be ascertained from 
parent, guardian or documentation; vaccine status was ascertained for 1172/2085 (56.2%) children ≤10 years. 
d




















Table 2: Participant characteristics associated with hepatitis B infection in the serosurvey: binomial 
logistic regression model 
Characteristic Univariate  
Odds ratio (95% CI) 
P value Multivariable modela 
Odds ratio (95% CI) 
P value 








0.09 (0.04 – 0.18) 
Reference 
1.82 (1.22 – 2.73) 
0.81 (0.45 – 1.46)  








1.80 (0.87 – 3.72) 
1.49 (0.56 – 3.98) 




 Born prior to vaccine 
 Born after vaccine  
 
Reference 













1.58 (1.00 – 2.49) 
2.73 (1.12 – 6.64) 






1.51 (0.75 – 3.02) 
2.89 (0.96 – 8.67) 











1.07 (0.72 – 1.59) 
0.63 (0.23 – 1.78) 
1.44 (0.57 – 3.61) 












 Paid employee 




0.93 (0.40 – 2.16) 
2.44 (1.28 – 4.64) 
2.20 (1.11 – 4.38) 
1.30 (0.62 – 2.72) 

























 Highest quintile 
 2nd highest quintile 
 Middle quintile 
 2nd Poorest quintile 
 Poorest quintile 
 
Reference 
1.21 (0.62 – 2.37) 
0.73 (0.36 – 1.49) 
1.11 (0.57 – 2.17) 






Multivariable model considers individuals aged ≥16 years and includes a cubic spline variable for age to 
account for change in prevalence with respect to age. 
b
Education, employment, marital status and 
socioeconomic status data are applicable to individuals aged >16 years. 
c
Socioeconomic quintiles are derived 




















Table 3: Characteristics of participants and outcome of community evaluation of HBV treatment 
eligibility  
Characteristic 
median (IQR) or n(%) 
 








Age, years 36 (29, 41) 39 (36, 47) 34 (27, 38) 
Sex, female 49 (52) 14 (58) 35 (51) 
CD4 count (cells/mm3)b  519 (412, 577)  
On ART  16/24 (67)  
On TDF or 3TC  16/24 (67)  
Symptoms/signs of CLD    
Signs of CLD 3 (3) 1 (4) 2 (3) 
Past medical history    
History of tuberculosis 7 (7) 6 (25) 1 (1) 
Diabetes 1 (1) 0 (0) 1 (1) 
Renal disease 1 (1) 0 (0) 1 (1) 
Hypertension 1 (1) 0 (0) 1 (1) 
Alcohol consumption    
Abstinent 59 (63) 12 (50) 47 (68) 
Low risk 23 (25) 9 (38) 14 (20) 
Hazardous 10 (11) 3 (13) 6 (9) 
Harmful 1 (1) 0 (0) 1 (1) 
Alcohol dependence 1 (1) 0 (0) 1 (1) 
Hepatitis D and C serology    
Anti-HDV 2 (2) 0 (0) 2 (3) 
HCV Ag/Ab 0 (0) 0 (0) 0 (0) 
Hepatitis B viral markers    
HBeAg 10 (11) 6 (25) 4 (6) 
HBV DNA (IU/ml) 81 (<32, 801) <32 (<32, <32) 215 (51, 2880) 
 HBV DNA> 2000 IU/ml 19 (20) 0 (0) 19 (28) 
 HBV DNA> 20,000 IU/ml 11 (12) 0 (0) 11 (16) 
ALT (IU/L) c 10 (8, 13) 12 (10, 15) 9 (8, 12) 



















 ALT>2x ULN 0 (0) 0 (0) 0 (0) 
Liver stiffness measurement (kPa) 4.8 (4.0, 6.4) 4.5 (4.0, 5.4) 5.1 (4.0, 6.9) 
 ≥7.9kPa 10 (11) 1 (4) 9 (9) 
 ≥9.5kPa 4 (4) 1 (4) 3 (4) 
a
One participant did not consent to HIV testing 
b
CD4 count available for 21/23 (91%) of HIV positive individuals 
c
 The assay upper limit of normal was 32 U/L. 
Abbreviations: IQR interquartile range; CD4 cluster of differentiation 4; ART antiretroviral therapy; TDF 
tenofovir disoproxil fumarate; CLD chronic liver disease; HCV hepatitis C virus; HDV hepatitis D virus; Ag/Ab 






















Figure 1 : Flowchart of census and recruitment to the serological survey and community HBV 




Figure 2: Distribution of age and sex in the serosurvey relative to the demographic census a 
 
 
a Serosurvey age distribution is layered over census distribution data. 
 
 





aVaccine coverage shown among serosurvey participants born after implementation of the vaccine in 
2002. Tabulated age and sex stratified prevalence data are shown in appendix 6. 
 
Figure 4: Outcomes of community clinical evaluation for HBV treatment eligibilitya 
Abbreviations: TDF tenofovir disoproxil fumarate ; 3TC lamivudine ; HBsAg hepatitis B surface 
antigen; HBV hepatitis B virus; WHO World Health Organization; EASL European Association for 
Study of the Liver; AASLD American Association for the Study of the Liver. a Area is proportional to 
the number of people in each group. Treatment eligibility criteria are considered only for HIV 











July 2016– October 2016 
n=97,386 
Serosurvey





 children <16 years 
Age ≥ 16 years
n=150 
Detailed clinical evaluation
July 2017- March 2019 
n=94 
56 (37%) excluded:
 21 (14%) could not be located 
 20 (13%) declined participation 
 9 (6%) moved out of area  
 4 (3%) died 
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